RhyGaze

RhyGaze is a clinical-stage biotechnology company developing gene therapy treatments to restore vision for people with retinal degenerative diseases. Its platform combines optogenetic proteins that engineer photosensitivity into mammalian cells with gene therapy delivery tools that install light-sensing machinery into human eye cells, technology originating at the Institute of Molecular and Clinical Ophthalmology Basel (IOB) in Switzerland. The team includes executives who helped develop and commercialize Luxturna, the first FDA-approved gene therapy for a genetic disease. RhyGaze operates from Basel, Switzerland and Philadelphia, Pennsylvania, and is backed by GV. As a therapeutics company it publishes no public developer API surface.

RhyGaze is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Biotechnology, Gene Therapy, and Ophthalmology.

🌐 Visit website 📡 Source on GitHub

5.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyLife SciencesBiotechnologyGene TherapyOphthalmologyOptogeneticsVision Restoration

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 5.7/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/rhygaze: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Resources

Company 1

The organization behind the API

Website

Website

Source (apis.yml)

aid: rhygaze
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/rhygaze.png
name: RhyGaze
description: RhyGaze is a clinical-stage biotechnology company developing gene therapy treatments to restore vision for people
  with retinal degenerative diseases. Its platform combines optogenetic proteins that engineer photosensitivity into mammalian
  cells with gene therapy delivery tools that install light-sensing machinery into human eye cells, technology originating
  at the Institute of Molecular and Clinical Ophthalmology Basel (IOB) in Switzerland. The team includes executives who helped
  develop and commercialize Luxturna, the first FDA-approved gene therapy for a genetic disease. RhyGaze operates from Basel,
  Switzerland and Philadelphia, Pennsylvania, and is backed by GV. As a therapeutics company it publishes no public developer
  API surface.
url: https://raw.githubusercontent.com/api-evangelist/rhygaze/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-21'
tags:
- Company
- Life Sciences
- Biotechnology
- Gene Therapy
- Ophthalmology
- Optogenetics
- Vision Restoration
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://rhygaze.com
x-enrichment:
  date: '2026-07-21'
  status: nochange
  artifacts_added: 0
  pass: local-v1